Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Jun;40(6):1514–1519. doi: 10.1128/aac.40.6.1514

Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction.

A E Heald 1, P H Hsyu 1, G J Yuen 1, P Robinson 1, P Mydlow 1, J A Bartlett 1
PMCID: PMC163359  PMID: 8726029

Abstract

The purpose of this study was to determine the safety and pharmacokinetics of lamivudine (3TC), a nucleoside analog that has shown potent in vitro and recent in vivo activity against human immunodeficiency virus. Sixteen human immunodeficiency virus-infected patients, six with normal renal function (creatinine clearance [CLCR], > or = 60 ml/min), four with moderate renal impairment (CLCR, 10 to 40 ml/min), and six with severe renal impairment (CLCR, < 10 ml/min), were enrolled in the study. After an overnight fast, patients were administered 300 mg of 3TC orally. Blood was obtained before 3TC administration and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 32, 40, and 48 h afterward. Timed urine collections were performed for patients able to produce urine. Serum and urine were assayed for 3TC by reverse-phase high-performance liquid chromatography with UV detection. Pharmacokinetic parameters were calculated by using standard noncompartmental techniques. The peak concentration of 3TC increased with decreasing renal function; geometric means were 2,524, 3,538, and 5,684 ng/ml for patients with normal renal function, moderate renal impairment, and severe renal impairment, respectively. The terminal half-life also increased with decreasing renal function; geometric means were 11.5, 14.1, and 20.7 h for patients with normal renal function, moderate renal impairment, and severe renal impairment, respectively. Both oral and renal clearances were linearly correlated with CLCR. A 300-mg dose of 3TC was well tolerated by all three patient groups. The pharmacokinetics of 3TC is profoundly affected by impaired renal function. Dosage adjustment, by either dose reduction or lengthening of the dosing interval, is warranted.

Full Text

The Full Text of this article is available as a PDF (261.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bourgoignie J. J., Meneses R., Ortiz C., Jaffe D., Pardo V. The clinical spectrum of renal disease associated with human immunodeficiency virus. Am J Kidney Dis. 1988 Aug;12(2):131–137. doi: 10.1016/s0272-6386(88)80008-8. [DOI] [PubMed] [Google Scholar]
  2. Coates J. A., Cammack N., Jenkinson H. J., Mutton I. M., Pearson B. A., Storer R., Cameron J. M., Penn C. R. The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother. 1992 Jan;36(1):202–205. doi: 10.1128/aac.36.1.202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  4. Eron J. J., Benoit S. L., Jemsek J., MacArthur R. D., Santana J., Quinn J. B., Kuritzkes D. R., Fallon M. A., Rubin M. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med. 1995 Dec 21;333(25):1662–1669. doi: 10.1056/NEJM199512213332502. [DOI] [PubMed] [Google Scholar]
  5. Glassock R. J., Cohen A. H., Danovitch G., Parsa K. P. Human immunodeficiency virus (HIV) infection and the kidney. Ann Intern Med. 1990 Jan 1;112(1):35–49. doi: 10.7326/0003-4819-112-1-35. [DOI] [PubMed] [Google Scholar]
  6. Harker A. J., Evans G. L., Hawley A. E., Morris D. M. High-performance liquid chromatographic assay for 2'-deoxy-3'-thiacytidine in human serum. J Chromatogr B Biomed Appl. 1994 Jul 1;657(1):227–232. doi: 10.1016/0378-4347(94)80092-8. [DOI] [PubMed] [Google Scholar]
  7. Hart G. J., Orr D. C., Penn C. R., Figueiredo H. T., Gray N. M., Boehme R. E., Cameron J. M. Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrob Agents Chemother. 1992 Aug;36(8):1688–1694. doi: 10.1128/aac.36.8.1688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Humphreys M. H., Schoenfeld P. Y. Renal complications in patients with the acquired immune deficiency syndrome (AIDS). Am J Nephrol. 1987;7(1):1–7. doi: 10.1159/000167420. [DOI] [PubMed] [Google Scholar]
  9. Morris D. M., Selinger K. Determination of 2'-deoxy-3'-thiacytidine (3TC) in human urine by liquid chromatography: direct injection with column switching. J Pharm Biomed Anal. 1994 Feb;12(2):255–264. doi: 10.1016/0731-7085(94)90037-x. [DOI] [PubMed] [Google Scholar]
  10. Pluda J. M., Cooley T. P., Montaner J. S., Shay L. E., Reinhalter N. E., Warthan S. N., Ruedy J., Hirst H. M., Vicary C. A., Quinn J. B. A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J Infect Dis. 1995 Jun;171(6):1438–1447. doi: 10.1093/infdis/171.6.1438. [DOI] [PubMed] [Google Scholar]
  11. Rao T. K., Friedman E. A., Nicastri A. D. The types of renal disease in the acquired immunodeficiency syndrome. N Engl J Med. 1987 Apr 23;316(17):1062–1068. doi: 10.1056/NEJM198704233161705. [DOI] [PubMed] [Google Scholar]
  12. Rao T. K., Friedman E. A. Renal syndromes in the acquired immunodeficiency syndrome (AIDS): lessons learned from analysis over 5 years. Artif Organs. 1988 Jun;12(3):206–209. doi: 10.1111/j.1525-1594.1988.tb02755.x. [DOI] [PubMed] [Google Scholar]
  13. Schinazi R. F., Chu C. K., Peck A., McMillan A., Mathis R., Cannon D., Jeong L. S., Beach J. W., Choi W. B., Yeola S. Activities of the four optical isomers of 2',3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrob Agents Chemother. 1992 Mar;36(3):672–676. doi: 10.1128/aac.36.3.672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Soudeyns H., Yao X. I., Gao Q., Belleau B., Kraus J. L., Nguyen-Ba N., Spira B., Wainberg M. A. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother. 1991 Jul;35(7):1386–1390. doi: 10.1128/aac.35.7.1386. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Yuen G. J., Morris D. M., Mydlow P. K., Haidar S., Hall S. T., Hussey E. K. Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J Clin Pharmacol. 1995 Dec;35(12):1174–1180. doi: 10.1002/j.1552-4604.1995.tb04043.x. [DOI] [PubMed] [Google Scholar]
  16. van Leeuwen R., Katlama C., Kitchen V., Boucher C. A., Tubiana R., McBride M., Ingrand D., Weber J., Hill A., McDade H. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J Infect Dis. 1995 May;171(5):1166–1171. doi: 10.1093/infdis/171.5.1166. [DOI] [PubMed] [Google Scholar]
  17. van Leeuwen R., Lange J. M., Hussey E. K., Donn K. H., Hall S. T., Harker A. J., Jonker P., Danner S. A. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS. 1992 Dec;6(12):1471–1475. doi: 10.1097/00002030-199212000-00008. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES